NERPRECCA

Serial Number 99017532
730

Registration Progress

Application Filed
Jan 24, 2025
Under Examination
May 13, 2025
Approved for Publication
Mar 18, 2025
Published for Opposition
Mar 18, 2025
Registered

Attorney Assistance

NOA E-Mailed - SOU Required
Due: Nov 13, 2025 9 days

Trademark Image

NERPRECCA

Basic Information

Serial Number
99017532
Filing Date
January 24, 2025
Published for Opposition
March 18, 2025
Drawing Code
4

Status Summary

Current Status
Active
Status Code
730
Status Date
Sep 11, 2025
Application
Pending
Classes
005

Rights Holder

Annexon, Inc.

03
Address
1400 Sierra Point Pkwy., Bldg. C, 2nd Fl
Brisbane, CA 94005

Ownership History

Annexon, Inc.

Original Applicant
03
Brisbane, CA

Annexon, Inc.

Owner at Publication
03
Brisbane, CA

Legal Representation

Attorney
Joshua S. Jarvis

USPTO Deadlines

Next Deadline
9 days remaining
NOA E-Mailed - SOU Required
Due Date
November 13, 2025
Extension Available
Until May 13, 2026

Application History

13 events
Date Code Type Description Documents
Sep 12, 2025 EXRA E NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED Loading...
Sep 11, 2025 EX1G S SOU EXTENSION 1 GRANTED Loading...
Sep 11, 2025 EXT1 S SOU EXTENSION 1 FILED Loading...
Sep 11, 2025 EEXT I SOU TEAS EXTENSION RECEIVED Loading...
May 13, 2025 NOAM E NOA E-MAILED - SOU REQUIRED FROM APPLICANT Loading...
Mar 18, 2025 NPUB E OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED Loading...
Mar 18, 2025 PUBO A PUBLISHED FOR OPPOSITION Loading...
Mar 12, 2025 NONP E NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED Loading...
Feb 21, 2025 CNSA P APPROVED FOR PUB - PRINCIPAL REGISTER Loading...
Feb 19, 2025 DOCK D ASSIGNED TO EXAMINER Loading...
Jan 24, 2025 NWOS I NEW APPLICATION OFFICE SUPPLIED DATA ENTERED Loading...
Jan 24, 2025 MAFR O APPLICATION FILING RECEIPT MAILED Loading...
Jan 24, 2025 NWAP I NEW APPLICATION ENTERED Loading...

Detailed Classifications

Class 005
Pharmaceutical preparations for the treatment of immune system related diseases and disorders, complement-mediated diseases and disorders, and neurological diseases and disorders; pharmaceutical preparations for the treatment of Guillain-Barré syndrome.

Classification

International Classes
005